UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Annals of oncology, 2023-08, Vol.34 (8), p.670-680

2023

Volltextzugriff (PDF)

SEOM clinical guidelines in early stage breast cancer (2018)

Clinical & translational oncology, 2019-01, Vol.21 (1), p.18-30

2019

Volltextzugriff (PDF)

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

European journal of cancer (1990), 2022-01, Vol.161, p.26-37

2022

Volltextzugriff (PDF)

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

Annals of oncology, 2014-11, Vol.25 (11), p.2173-2178

2014

Volltextzugriff (PDF)

Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report

Current problems in cancer. Case reports, 2021-12, Vol.4, p.100097, Article 100097

2021

Volltextzugriff (PDF)

Information and communication technology systems to improve quality of life and safety of Alzheimer's disease patients: a multicenter international survey

Journal of Alzheimer's disease, 2011-01, Vol.23 (1), p.131-141

2011

Volltextzugriff (PDF)

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single‐arm trial

Journal of human nutrition and dietetics, 2019-08, Vol.32 (4), p.468-479

2019

Volltextzugriff (PDF)

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

Clinical & translational oncology, 2019-04, Vol.21 (4), p.459-466

2019

Volltextzugriff (PDF)

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain

British journal of cancer, 2012-10, Vol.107 (8), p.1249-1256

2012

Volltextzugriff (PDF)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial

British journal of cancer, 2009-02, Vol.100 (3), p.442-449

2009

Volltextzugriff (PDF)

Influence of the 2019-novel coronavirus pandemic on the management of breast cancer

Clínica e investigación en ginecología y obstetricia, 2020-07, Vol.47 (3), p.89-90

2020

Volltextzugriff (PDF)

DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer

Tumor biology, 2016-10, Vol.37 (10), p.13435-13443

2016

Volltextzugriff (PDF)

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

Journal of patient-reported outcomes, 2019-12, Vol.3 (1), p.72-10, Article 72

2019

Volltextzugriff (PDF)

339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer

Annals of oncology, 2021-09, Vol.32, p.S515-S515

2021

Volltextzugriff (PDF)

Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound‐guided transbronchial needle aspiration

Cytopathology (Oxford), 2018-02, Vol.29 (1), p.35-40

2018

Volltextzugriff (PDF)

1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)

Annals of oncology, 2021-09, Vol.32, p.S1105-S1105

2021

Volltextzugriff (PDF)

Abstract P5-15-09: Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-15-09

2019

Volltextzugriff (PDF)

Cáncer oculto de la mama. Caso clínico y revisión de la literatura

Clínica e investigación en ginecología y obstetricia, 2012, Vol.39 (1), p.21-28

2012

Volltextzugriff (PDF)

0145 First safety data from a randomised phase III trial comparing adjuvant epirubicin–cyclophosphamide → docetaxel (EC → T) vs ET → capecitabine (X) in N+ operable breast cancer (BC)

Breast (Edinburgh), 2009, Vol.18, p.S55-S55

2009

Volltextzugriff (PDF)

Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS5-07-GS5-07

2019

Volltextzugriff (PDF)

Abstract OT2-01-06: Phase III study of p albociclib (PD-0332991) in combination with e ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with r esistance to a romatase inhibitors. “The PEARL study” (GEICAM/2013-02)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-06-OT2-01-06

2017

Volltextzugriff (PDF)

Abstract P6-11-04: Use of Mammaprint© (MMP) genetic signature in early breast cancer patients. Economic analisys of a 129 patient cohort treated in three Spanish hospitals

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-11-04

2016

Volltextzugriff (PDF)

Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia

Journal of medical economics, 2007, Vol.10 (1), p.27-39

2007

Volltextzugriff (PDF)

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial

Annals of oncology, 2013-05, Vol.24 (5), p.1203-1211

2013

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(160)

Publikationsform

Artikel
(174)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(58)
Humans
(42)
Female
(32)
Male
(31)
Biological And Medical Sciences
(28)
Middle Aged
(28)
Medical Sciences
(27)
Oncology
(27)
Adult
(26)
Aged
(23)
Animals
(16)
Breast Cancer
(16)
Rats
(15)
Breast Neoplasms - Drug Therapy
(13)
Rats, Wistar
(12)
Aged, 80 And Over
(11)
Breast Neoplasms - Pathology
(10)
Gastroenterology & Hepatology
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

SEOM clinical guidelines in early stage breast cancer (2018)

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report

Information and communication technology systems to improve quality of life and safety of Alzheimer's disease patients: a multicenter international survey

Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single‐arm trial

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial

Influence of the 2019-novel coronavirus pandemic on the management of breast cancer

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer

Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound‐guided transbronchial needle aspiration

1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)

Abstract P5-15-09: Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain

Cáncer oculto de la mama. Caso clínico y revisión de la literatura

0145 First safety data from a randomised phase III trial comparing adjuvant epirubicin–cyclophosphamide → docetaxel (EC → T) vs ET → capecitabine (X) in N+ operable breast cancer (BC)

Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

Abstract P6-11-04: Use of Mammaprint© (MMP) genetic signature in early breast cancer patients. Economic analisys of a 129 patient cohort treated in three Spanish hospitals

Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial

Suchergebnisse filtern